2-羟基-N-(1-甲基乙基)-丙酰胺 | 6280-17-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-羟基-N-(1-甲基乙基)-丙酰胺
• 英文名称: N-(1-Methylethyl)-2-hydroxypropanamide
• 英文别名: N-isopropyl-lactamide；N-Isopropyl-lactamid；Milchsaeure-isopropylamid；N-(isopropyl) lactamide；2-Hydroxy-n-(propan-2-yl)propanamide；2-hydroxy-N-propan-2-ylpropanamide
• CAS: 6280-17-7
• 化学式: C₆H₁₃NO₂
• mdl: MFCD12137905
• 分子量: 131.175
• InChiKey: PLSSYQFNLOOTSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乳酸甲酯 、 异丙胺 生成 2-羟基-N-(1-甲基乙基)-丙酰胺
  参考文献：
  名称：

  PREPARATION OF N-SUBSTITUTED LACTAMIDES BY AMINOLYSIS OF METHYL LACTATE^{2, 3}

  摘要：

  DOI：

  10.1021/jo01148a013

文献信息

• FORUMLATIONS
  申请人：Bell Gordon Alastair

  公开号：US20090227453A1

  公开（公告）日：2009-09-10

  This invention relates to the use of lactamide compounds of formula (I): CH 3 CH(OH)C(═O)NR 1 R 2 , where R 1 and R 2 are each independently hydrogen; or C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C 1-5 alkoxy, morpholinyl and NR 3 R 4 where R 3 and R 4 are each independently C 1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C 1-3 alkyl; or R 1 and R 2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C 1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.

  这项发明涉及使用式（I）的乳酰胺化合物：CH3CH(OH)C(═O)NR1R2，其中R1和R2分别独立地是氢；或C1-6烷基，C2-6烯基或C3-6环烷基，每种基团可选择地被最多三个取代基取代，这些取代基独立地选自苯基、羟基、C1-5烷氧基、吗啉基和NR3R4，其中R3和R4分别独立地是C1-3烷基；或苯基可选择地被最多三个取代基取代，这些取代基独立地选自C1-3烷基；或R1和R2与它们连接的氮原子一起形成吗啉基、吡咯啉基、哌啶基或氮杂环庚基环，每种环可选择地被最多三个取代基取代，这些取代基独立地选自C1-3烷基，在配方中减少与其他配方成分相关的毒性；使用某些乳酰胺化合物作为溶剂，特别是在配方中，尤其是在农药配方和环保配方中；新型乳酰胺化合物；以及制备乳酰胺化合物的方法。
• [EN] PROCESS FOR MANUFACTURING N,N-DIALKYL LACTAMIDE<br/>[FR] PROCÉDÉ POUR LA FABRICATION DE N,N-DIALKYLLACTAMIDE
  申请人：PURAC BIOCHEM BV

  公开号：WO2010037776A1

  公开（公告）日：2010-04-08

  The present invention pertains to a process for manufacturing dialkyl lactamide comprising the steps of reacting lactide and dialkylamine selected from one or more of dimethylamine, diethylamine, and methylethylamine to form a reaction mixture which comprises dialkyl lactamide selected from N, N-dimethyl lactamide, N,N-diethyl lactamide, and N,N-methylethyl lactamide, N,N-dialkyl lactoyl lactamide, and dialkylamine, subjecting the reaction mixture to a separation step to form a product stream comprising N,N-dialkyl lactamide, a first recycle stream comprising dialkylamine and a second recycle stream comprising N,N-dialkyl lactoyl lactamide, feeding the recycle streams to the reaction step, and isolating the product stream. The process allows the manufacture of N, N-dimethyl lactamide, N,N-diethyl lactamide, and N,N-methylethyl lactamide on commercial scale.

  本发明涉及一种制造二烷基内酰胺的方法，包括以下步骤：将内酯和二烷基胺（所选自二甲胺、二乙胺和甲乙胺）反应，形成反应混合物，其中包括所选自N，N-二甲基内酰胺、N，N-二乙基内酰胺、N，N-甲乙基内酰胺、N，N-二烷基内酰基内酰胺和二烷基胺的二烷基内酰胺；将反应混合物经过分离步骤，形成产品流，其中包括N，N-二烷基内酰胺、第一循环流，包括二烷基胺和第二循环流，包括N，N-二烷基内酰基内酰胺；将循环流送回反应步骤，隔离产品流。该方法允许商业化生产N，N-二甲基内酰胺、N，N-二乙基内酰胺和N，N-甲乙基内酰胺。
• COMPOUNDS USEFUL FOR INHIBITING CHK1
  申请人：Keegan Kathleen S.

  公开号：US20100105683A1

  公开（公告）日：2010-04-29

  Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.

  本发明公开了用于治疗与DNA损伤或DNA复制中的损伤有关的疾病和病症的芳基和杂环基取代脲化合物。本发明还公开了制备该化合物的方法以及它们作为治疗剂的用途，例如，在治疗癌症和其他以DNA复制缺陷、染色体分离或细胞分裂为特征的疾病中。
• AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1
  申请人：HOLCOMB Ryan C.

  公开号：US20120238540A1

  公开（公告）日：2012-09-20

  The invention relates to certain amino-pyrimidine compounds that inhibit IKK epsilon and/or TBK1, methods of making such compounds, pharmaceutical compositions comprising such compounds, and the use of these compounds in treating a variety of diseases and disorders.

  本发明涉及一些氨基嘧啶化合物，可抑制IKK epsilon和/或TBK1，制备这种化合物的方法，包含这种化合物的药物组合物，以及在治疗各种疾病和疾病失调中使用这些化合物的方法。
• AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON
  申请人：Alzheimer's Institute of America

  公开号：US20150352108A1

  公开（公告）日：2015-12-10

  The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).

  该发明涉及某些氨基嘧啶化合物，其抑制TBK1和/或IKK epsilon，因此可能在治疗炎症、癌症、感染性休克和/或原发性开角青光眼（POAG）方面找到应用。